#Germany #Zentiva #APONTIS PHARMA #Frankfurt am Main #Pharma Acquisition

Zentiva's Strategic Move into the Pharmaceutical Sector

In a recent development, Zentiva AG, which is a fully owned subsidiary of Zentiva Pharma GmbH, has successfully completed its voluntary public purchase offer for shares of APONTIS PHARMA AG. This strategic move marks a significant milestone for Zentiva, bolstering its position in the European pharmaceutical landscape. With its headquarters located in Frankfurt am Main, Germany, Zentiva is part of a robust network dedicated to providing high-quality and affordable medicines across Europe.

As a result of this acquisition, Zentiva now holds approximately 83.57% of the capital and around 85.27% of the voting rights for APONTIS PHARMA. This increase in shares solidifies Zentiva's influence and decision-making capability within APONTIS, paving the way for enhanced operational synergies between the two companies.

The acquisition conditions, as laid out in the offer document published previously, were either successfully met or waived ahead of the negotiation deadline, allowing for a smooth settlement process. Both Zentiva and APONTIS PHARMA have come to a mutual understanding that the management board of APONTIS will, as far as the law allows and its fiduciary duties permit, cease the inclusion of APONTIS shares in the open market trading immediately following the deal closure. This move eliminates the need for a separate delisting offer, streamlining future operations.

Investors interested in selling their shares in APONTIS are encouraged to reach out directly to Zentiva via their provided communication channels. The public can access further insights and detailed information regarding the acquisition on their dedicated website.

About Zentiva

Zentiva's commitment to healthcare is evident in its mission to develop, manufacture, and deliver high-quality medicines to over 100 million patients in Europe. The company operates four fully owned manufacturing facilities and collaborates with a broad array of external partners to ensure a reliable supply chain. Zentiva focuses on critical therapeutic areas such as Cardiology, Diabetes, Oncology, and Respiratory Care. The company also aims to expand its portfolio in self-care solutions, ensuring a comprehensive approach to health management.

Employing nearly 5,000 individuals, Zentiva prides itself on fostering a thriving workplace environment. The company's ethos revolves around inclusivity, encouraging employees to bring their authentic selves to work, thus maximizing their contributions.

About APONTIS PHARMA

APONTIS PHARMA, known for its innovative Single Pill combinations, specializes in creating medications that simplify treatment regimens for patients in Germany. This unique method involves combining two or three active ingredients into a single daily dose, promoting better adherence to prescribed therapies. Single Pill approaches have proven to enhance treatment outcomes, reduce complications, and ultimately improve the quality of life for patients dealing with chronic conditions.

Since its inception in 2013, APONTIS PHARMA has developed a diverse range of products, particularly targeting cardiovascular diseases such as hypertension and lipid disorders. The firm is recognized for its contribution to public health and adheres to several international treatment guidelines, reaffirming its role in the pharmaceutical sector.

With the successful acquisition of APONTIS PHARMA by Zentiva, both companies are poised for further growth and innovation in the pharmaceutical industry, ultimately benefiting healthcare outcomes across Europe.

For more information about Zentiva, visit Zentiva or APONTIS PHARMA.